Filtered By:
Drug: Cilostazol

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 208 results found since Jan 2013.

Cilostazol for the Prevention of Acute Progressing Stroke: A Multicenter, Randomized Controlled Trial
Conclusions: Cilostazol failed to show a preventive effect against acute progressing stroke. However, the tendency to reduce progressing stroke and the results of stratified analyses may encourage additional studies to clarify the effect of cilostazol in the treatment of acute ischemic stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - April 1, 2013 Category: Neurology Authors: Hiroaki Shimizu, Teiji Tominaga, Akira Ogawa, Takamasa Kayama, Kazuo Mizoi, Kiyoshi Saito, Yasuo Terayama, Kuniaki Ogasawara, Etsuro Mori, Tohoku Acute Stroke Progressing Stroke Study Group Tags: Original Articles Source Type: research

Efficacy of Antiplatelet Therapy in Secondary Prevention Following Lacunar Stroke: Pooled Analysis of Randomized Trials Clinical Sciences
Conclusions— Our results suggest that any of the single antiplatelet agents compared with placebo in the included trials is adequate for secondary stroke prevention after lacunar stroke. Dual antiplatelet therapy should not be used for long-term stroke prevention in this stroke subtype.
Source: Stroke - March 23, 2015 Category: Neurology Authors: Kwok, C. S., Shoamanesh, A., Copley, H. C., Myint, P. K., Loke, Y. K., Benavente, O. R. Tags: Antiplatelets Clinical Sciences Source Type: research

Rationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage (PICASSO) study: A randomized controlled trial
DiscussionPreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage is the largest secondary stroke prevention trial for informing antiplatelet therapy and lipid management in patients at high risk of haemorrhagic stroke.
Source: International Journal of Stroke - June 4, 2015 Category: Neurology Authors: Keun‐Sik Hong, Bum Joon Kim, Jun‐Young Lee, Sun U. Kwon, Tags: Protocol Source Type: research

The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double‐blind, placebo‐controlled multicenter trial
ConclusionThe SPAD trial is the first study to evaluate the safety and efficacy of dual antiplatelet agents, aspirin plus cilostazol, in comparison with aspirin alone in patients with both ischemic stroke or TIA and PAD. Results from this trial will provide important information on the merit of adding cilostazol to aspirin for slowing down progression of atherosclerosis in patients with ischemic stroke and PAD.
Source: International Journal of Stroke - November 14, 2014 Category: Neurology Authors: Jiann‐Shing Jeng, Yu Sun, Jiunn‐Tay Lee, Ruey‐Tay Lin, Chih‐Hung Chen, Helen L. Po, Huey‐Juan Lin, Chung‐Hsiang Liu, Ming‐Hui Sun, Mu‐Chien Sun, Chang‐Ming Chern, Li‐Ming Lien, Hou‐Chang Chiu, Han‐Hwa Hu, Hung‐Yi Chiou, Sien‐Ts Tags: Protocols Source Type: research

Long-Term Antiplatelet Mono- and Dual Therapies After Ischemic Stroke or Transient Ischemic Attack: Network Meta-Analysis Stroke
Conclusions Long-term monotherapy was a better choice than long-term dual therapy, and cilostazol had the best risk–benefit profile for long-term secondary prevention after stroke or transient ischemic attack. More randomized controlled trials in non–East Asian patients are needed to determine whether long-term use of cilostazol is the best option for the prevention of recurrent stroke.
Source: JAHA:Journal of the American Heart Association - August 24, 2015 Category: Cardiology Authors: Xie, W., Zheng, F., Zhong, B., Song, X. Tags: Stroke Source Type: research

Homocysteine as a Predictor of Early Neurological Deterioration in Acute Ischemic Stroke Brief Reports
Conclusions— Patients with acute stroke with elevated serum homocysteine levels are at an increased risk for END.
Source: Stroke - February 24, 2014 Category: Neurology Authors: Kwon, H.-M., Lee, Y.-S., Bae, H.-J., Kang, D.-W. Tags: Risk Factors, Epidemiology Brief Reports Source Type: research

Design and Rationale of the Intima-Medial Thickness Sub-Study of the PreventIon of CArdiovascular Events in iSchemic Stroke Patients with High Risk of Cerebral hemOrrhage (PICASSO-IMT) Study
Atherosclerosis is one of the main mechanisms of stroke and cardiovascular diseases and is associated with increased risk of recurrent stroke and cardiovascular events. Intima-medial thickness (IMT) is a well-known surrogate marker of atherosclerosis and has been used to predict stroke and cardiovascular events. However, the clinical significance of IMT and IMT change in stroke has not been investigated in well-designed studies. The PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage —Intima-Media Thickness (PICASSO-IMT) sub-study is designed to investigate the effects of...
Source: Journal of Stroke and Cerebrovascular Diseases - July 21, 2017 Category: Neurology Authors: Woo-Keun Seo, Yong Jae Kim, Juneyoung Lee, Sun U. Kwon, PICASSO Investigators Source Type: research

Design and Rationale for a Cognitive Outcome Substudy in Ischemic Stroke Patients with High Risk of Cerebral Hemorrhage
Cognitive impairment and dementia are common disabilities after stroke and are associated with increased risks of mortality and recurrent stroke. The prevention of dementia and preserving cognitive function are also important in stroke patients, but its strategy is not established yet. This PICASSO-COG (PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage for reducing COGnitive decline) substudy aims to assess the effects of cilostazol and/or probucol on cognitive function.
Source: Journal of Stroke and Cerebrovascular Diseases - May 31, 2016 Category: Neurology Authors: Kyung-Ho Yu, Keun-Sik Hong, Mi-Sun Oh, Juneyoung Lee, Ji Sung Lee, Sun U. Kwon, PICASSO investigators Source Type: research

Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open‐label, parallel‐group trial
DiscussionThe CSPS.com is expected to provide evidence indicating whether secondary IS prevention in high‐risk patients can be improved by using DAPT involving cilostazol.
Source: International Journal of Stroke - December 8, 2014 Category: Neurology Authors: Kazunori Toyoda, Shinichiro Uchiyama, Haruhiko Hoshino, Kazumi Kimura, Hideki Origasa, Hiroaki Naritomi, Kazuo Minematsu, Takenori Yamaguchi, Tags: Protocols Source Type: research

Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis
Cilostazol has promise as an alternative to aspirin for secondary stroke prevention given its vasodilatory and anti-inflammatory properties in addition to platelet aggregation inhibition. We aimed to conduct a systematic review and meta-analysis to estimate the efficacy and safety of cilostazol compared to aspirin for stroke prevention in patients with previous stroke or transient ischemic attack (TIA).
Source: Journal of Stroke and Cerebrovascular Diseases - December 31, 2020 Category: Neurology Authors: Michelle P. Lin, James F. Meschia, Neethu Gopal, Kevin M. Barrett, Owen A. Ross, Nil üfer Ertekin-Taner, Thomas G. Brott Source Type: research

Cilostazol Ameliorates Warfarin-Induced Hemorrhagic Transformation After Cerebral Ischemia in Mice Basic Sciences
Conclusions— Cilostazol reduced the warfarin-related risk of HT after ischemia by protecting the vascular endothelial cells. This result suggested that cilostazol administration in patients with acute ischemic stroke might reduce HT.
Source: Stroke - September 23, 2013 Category: Neurology Authors: Kitashoji, A., Egashira, Y., Mishiro, K., Suzuki, Y., Ito, H., Tsuruma, K., Shimazawa, M., Hara, H. Tags: Cerebrovascular disease/stroke, Animal models of human disease, Other anticoagulants, Intracerebral Hemorrhage, Anticoagulants Basic Sciences Source Type: research

Efficacy and Safety of Cilostazol Therapy in Ischemic Stroke: A Meta-analysis
Antiplatelet therapy is recommended for patients who have experienced ischemic stroke. We performed a meta-analysis to compare the efficacy and safety of cilostazol with other antiplatelet therapies in patients with ischemic stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - March 24, 2015 Category: Neurology Authors: Liang Tan, Barnhart Margaret, John H. Zhang, Rong Hu, Yi Yin, Liu Cao, Hua Feng, Yanqi Zhang Source Type: research

Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines
Stroke Vasc Neurol. 2022 Apr 7:svn-2021-001166. doi: 10.1136/svn-2021-001166. Online ahead of print.ABSTRACTAntiplatelet therapy is one of the mainstays for secondary stroke prevention. This narrative review aimed to highlight the current evidence and recommendations of antiplatelet therapy for stroke prevention.We conducted advanced literature search for antiplatelet therapy. Landmark studies and randomised controlled trials evaluating antiplatelet therapy for secondary stroke prevention are reviewed. Results from Cochrane systematic review, pooled data analysis and meta-analysis are discussed.Single-antiplatelet therapy ...
Source: Atherosclerosis - April 8, 2022 Category: Cardiology Authors: Jay Shah Shimeng Liu Wengui Yu Source Type: research